AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02467348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Intravenous albumin 8 gms/L of ascitic fluid
Study NCT02467348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascitic fluid
Study NCT02467348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascitic fluid
Study NCT00140231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuLeptin
Description: recombinant human leptin
Study NCT00140231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: r-metHuLeptin
Description: recombinant human leptin
Study NCT00140231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo (no active drug)
Study NCT00140231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (no active drug)
Study NCT02537626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia ALS Laser
Description: The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
Study NCT02537626 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
Study NCT00221247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture
Study NCT04643509 — intervention group
Intervention type: DEVICE
Intervention: Niccomo
Description: Niccomo monitoring added to pulmonary arterial catheter monitoring
Study NCT02884726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986148
Description: Specified dose on specified days
Study NCT02858830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High fat mixed meal
Study NCT00975507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
Study NCT00975507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: a single 0.5 mL subcutaneous placebo injection at Day 0
Study NCT00975507 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varivax
Description: a single 0.5 mL subcutaneous injection of Varivax at Day 0
Study NCT00975507 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
Study NCT06420895 — intervention group
Intervention type: OTHER
Intervention: Clinical follow-up
Description: Clinical follow-up of patients
Study NCT06420895 — intervention group
Intervention type: OTHER
Intervention: Transthoracic Echocardiogram (TTE)
Description: Transthoracic Echocardiogram
Study NCT06420895 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging
Study NCT06420895 — intervention group
Intervention type: OTHER
Intervention: Transesophageal echocardiogram (TEE)
Description: Transesophageal echocardiogram
Study NCT03329443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: each patient will receive 200 mg of spironolactone as per his/her angiography premedications
Study NCT03329443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Each patient will receive a placebo tablet as per his/her angiography premedications
Study NCT02259998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Persantin® new formulation
Study NCT01499355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral corticosteroids
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Study NCT01499355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral corticosteroids
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Study NCT02259998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Persantin® commercial formulation
Study NCT00293722 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study NCT02530203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation System
Description: High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
Study NCT02530203 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Holter Recording_ NEMon DR220 Holter Recorders
Description: To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
Study NCT02530203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter Recording_ NEMon DR220 Holter Recorders
Description: To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
Study NCT01062633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A, erythritol
Description: 2,5 g 3 times a day
Study NCT01062633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: 2,5 g 3 times a day
Study NCT01062633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C, sorbitol
Description: 2,5 g 3 times aday
Study NCT01446016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
Study NCT01446016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
Study NCT01446016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
Study NCT01446016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
Study NCT04498455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotin
Description: Fructo-oligosaccharide dietary supplement powder
Study NCT04498455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotin
Description: Fructo-oligosaccharide dietary supplement powder
Study NCT03492788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECGI-optimized VV-offset
Description: ECGI guided optimization of VV offset programming of CRT device
Study NCT03492788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zero VV-offset
Description: Standard-of-care nominal (zero VV-offset) programming of CRT device
Study NCT04780308 — intervention group
Intervention type: PROCEDURE
Intervention: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires
Description: The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
Study NCT03113253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT03113253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride to mimic tranexamic acid
Study NCT03406260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.
Study NCT03406260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT02322138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1 Infant Formula
Description: Ready to feed infant formula to be fed ad-libitum
Study NCT02322138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 2 Infant Formula
Description: Ready to feed infant formula to be fed ad-libitum
Study NCT02322138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference Group
Description: Breast fed ad libitum
Study NCT05781776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago exercises and core strengthening
Description: Otago exercise program consisted of strengthening and balance exercises. The strengthening exercises focus on major lower limb muscles. Progression of exercises was done by increasing the duration and then intensity.~Balance exercises involved knee bends, backward walking, walking, and turning around, sideways walking, tandem stance (heel to toe), tandem walk (heal to toe walk), one leg stand, heel walking, toe walk, heel to toe walking backward, sit to stand and stair walking. Balance exercises progressed with varying levels of support depending on their balance and confidence. The individuals repeated each exercise 10 times.
Study NCT05781776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gaze stability exercises and core strengthening
Description: The exercise protocol in Gaze Stability exercises included adaptation exercises and substitution exercises. In adaptation exercises, individuals performed rapid, active head rotations while watched a visual target with the target remaining stationary. Substitution exercises, individual performed eye-head movements between targets with the goal of seeing clearly during the task. That target moved in the opposite direction of head movement.~Adaptation exercises included: Horizontal and vertical (stationary target) viewing exercises done with a near target, sitting. Horizontal and vertical (stationary target) viewing exercises done with near and far targets (6-10 feet), sitting. Horizontal and vertical (stationary target) viewing exercises were done with near and far targets, standing.
Study NCT02438319 — intervention group
Intervention type: OTHER
Intervention: manual planimetry
Description: Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
Study NCT02438319 — intervention group
Intervention type: OTHER
Intervention: automated planimetry
Description: Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
Study NCT01080378 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dietary and Exercise Intervention
Description: Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
Study NCT02189356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise programme
Description: The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
Study NCT02189356 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard care
Description: standard pregnancy follow up
Study NCT01363167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400 IU Cholecalciferol- Vitamin D Daily
Description: Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
Study NCT01363167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 400 IU Cholecalciferol- Vitamin D Daily
Description: Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
Study NCT01376349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasterone
Description: Applied vaginally
Study NCT01376349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied vaginally
Study NCT00162032 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sestamibi
Description: Sestamibi
Study NCT02442713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: fluvoxamine: 50-300mg/day
Study NCT00922103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileal Neo Rectal Anastomosis
Description: Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
Study NCT00922103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileal Pouch Anal Anastomosis
Description: Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
Study NCT04027231 — intervention group
Intervention type: OTHER
Intervention: analysis of the synovial fluid
Description: Electrochemical cell analysing the patients' synovial fluid whenever an invasive intervention is medically prescribed
Study NCT00882453 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Intravenous therapy according to product information
Study NCT02701426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity and nutritional counseling
Description: The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
Study NCT01966393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-hours intervention
Description: Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
Study NCT03513874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
Study NCT03513874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Patients will continue insulin therapy following physicians' instructions.
Study NCT03513874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Patients will continue insulin therapy following physicians' instructions.
Study NCT03952806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdiperstat
Description: 300mg 2 oral tablets, twice daily
Study NCT03952806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02467218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
Study NCT01736085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
Study NCT01736085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher
Description: Subjects will receive a voucher for nicotine patches.~Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
Study NCT01736085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
Study NCT01742598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico Transapical Aortic Valve System
Study NCT02136420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Subject receives promethazine
Study NCT02136420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyper gravity training
Description: Subject receives hypergravity training before testing
Study NCT02136420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02136420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02136420 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No hypergravity training
Description: Subjects do not receive normal Earth gravity
Study NCT02136420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No hypergravity training
Description: Subjects do not receive normal Earth gravity
Study NCT00003469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT01966016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacing
Description: In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.~In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared
Study NCT02057185 — intervention group
Intervention type: BEHAVIORAL
Intervention: Study questionnaire
Description: Questionnaire based on work situation of enrolled patients.
Study NCT02057185 — intervention group
Intervention type: BEHAVIORAL
Intervention: SF-36 Questionnaire
Description: Version 1.6
Study NCT01065727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mitoxantrone - immunomodulator
Description: mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
Study NCT01065727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: natalizumab
Description: monthly natalizumab during 3 years